性别肯定激素治疗对跨性别者凝血指标的影响
该研究在98名跨性别女性和100名跨性别男性中,于性别肯定激素治疗(GAHT)12个月前后检测凝血相关指标。跨性别女性GAHT后出现促凝改变,表现为FIX、FXI升高和蛋白C下降;跨性别男性未见明显促凝改变。
要点
- 跨性别女性GAHT 12个月后FIX平均升高9.6 IU/dL、FXI升高13.5 IU/dL、蛋白C下降7.7 IU/dL。
- 跨性别女性凝血指标变化受给药途径(口服vs经皮)和年龄影响。
- 跨性别男性GAHT后整体无促凝改变,给药途径间差异小。
核心结论
- 跨性别女性GAHT导致促凝改变,可能促成观察到的静脉血栓栓塞风险增加。
- 跨性别男性GAHT未伴随明显促凝改变,对VTE风险提供一定 reassurance。
研究设计与样本
- 在98名跨性别女性和100名跨性别男性中,于GAHT前和12个月后测量凝血指标。
- 跨性别女性使用口服或经皮雌二醇联合抗雄激素,跨性别男性使用经皮或肌注睾酮。
- 用95%CI估计凝血指标的平均配对差异,用线性回归评估给药途径和年龄的影响。
主要发现
- 跨性别女性GAHT后FIX平均升高9.6 IU/dL(95%CI 3.1-16.0),FXI升高13.5 IU/dL(95%CI 9.5-17.5),蛋白C下降7.7 IU/dL(95%CI -10.1至-5.2)。
- 跨性别女性凝血指标变化受给药途径(口服vs经皮)和年龄影响。
- 跨性别女性12个月后性激素结合球蛋白水平较高与活化蛋白C抵抗较低相关。
- 跨性别男性GAHT后变化整体无促凝性,且受年龄影响。
- 跨性别男性给药途径(经皮vs肌注)差异小。
临床怎么用
- 对跨性别女性启动GAHT时应评估VTE风险,关注促凝指标变化。
- 给药途径和年龄可能影响跨性别女性GAHT的凝血影响,需个体化考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The transgender population that uses gender-affirming hormone therapy (GAHT) is rapidly growing. The (side) effects of GAHT are largely unknown. We examined the effect of GAHT on coagulation parameters associated with venous thromboembolism (VTE) risk. METHODS: Factor (F)II, FIX, FXI, protein (p)C and free pS, fibrinogen, hematocrit, sex hormone-binding globulin, and normalized activated protein C ratio were measured in 98 transwomen (male sex at birth, female gender identity) and 100 transmen (female sex at birth, male gender identity) before and after 12 months of GAHT (oral or transdermal estradiol and anti-androgens in transwomen, transdermal or intramuscular testosterone in transmen). Mean paired differences in coagulation measurements were estimated with 95% confidence intervals (95% CI). Differences for route of administration and age were assessed with linear regression. RESULTS: After GAHT, transwomen had more procoagulant profiles with a mean increase in FIX: 9.6 IU/dL (95% CI 3.1-16.0) and FXI: 13.5 IU/dL (95% CI 9.5-17.5), and a decrease in pC: -7.7 IU/dL (95% CI -10.1 to -5.2). Changes in measures of coagulation were influenced by route of administration (oral vs. transdermal) and age. A higher sex-hormone binding globulin level after 12 months was associated with a lower activated protein C resistance. In transmen, changes were not procoagulant overall and were influenced by age. Differences for route of administration (transdermal vs. intramuscular) were small. CONCLUSIONS: GAHT in transmen was not associated with apparent procoagulant changes, which provides some reassurance regarding VTE risk. In transwomen, GAHT resulted in procoagulant changes, which likely contributes to the observed increased VTE risk.
引用
- Scheres LJJ, Selier NLD, Nota NM, et al. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. J Thromb Haemost. 2021. PMID: 33527671. doi:10.1111/jth.15256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。